Sunitinib
- PDF / 141,551 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 72 Downloads / 147 Views
1
S
Thyroid disorders: case report A 63-year-old woman developed thyroid disorders after receiving treatment with sunitinib. The woman, who had a history of renal carcinoma with pulmonary metastases, was admitted with a painful goitre. She had received six cycles of treatment with sunitinib 50 mg/day for 4 weeks, followed by 2 weeks without treatment [route not stated]. Five months after receiving sunitinib therapy, she developed a painful swelling in her neck. Analysis revealed decreased levels of TSH, elevated free thyroxine (T4) and free triiodothyronine (T3), a sedimentation rate of 35 mm/h and a thyroglobulin level of 42.3 ng/mL. CT scan showed a hypodensity in the central area of the thyroid. Ultrasound revealed a heterogeneous thyroid, consistent with thyroiditis and confirmed a goitre of 65cm3. The woman received treatment with beta-blockers. Ten days later, her levels of free T4 and free T3 had decreased, while TSH levels increased and thyroid peroxidase antibodies were detected. Her sedimentation rate was 24 mm/h and her thyroglobulin level was 27.9 ng/mL. Ultrasound results remained unchanged. She started receiving levothyroxine sodium and her thyroid function normalised. Author comment: "In this observation, a thyroid cytotoxic or ischemic effect of sunitinib could explain the transient thyrotoxicosis and CT scan picture." Velayoudom-Cephise F-L, et al. A CT scan aspect of "hypodense thyroid gland" after sunitinib treatment for metastatic carcinoma of the kidney. Journal of Clinical Endocrinology and Metabolism 96: 590-591, No. 3, Mar 2011. Available from: 803052621 URL: http://dx.doi.org/10.1210/jc.2010-1519 - Guadeloupe
0114-9954/10/1346-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 9 Apr 2011 No. 1346
Data Loading...
